TET2 as a diagnostic and prognostic marker in hematopoietic neoplasms

US10662482B2 · kind B2 · utility

Assignees

• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• INSTITUT GUSTAVE ROUSSY · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
• CENTRE HENRI BECQUEREL · FR
• UNIVERSITE DE PARIS DESCARTES · FR
• Universite Pierre Et Marie Curie (Paris 6) · FR
• UNIVERSITÉ PARIS-SUD · DE

Inventors

• Franck Viguie · Deuil-la-Barre, FR
• Olivier Bernard · Vanves, FR
• Michaela Fontenay · Paris, FR
• Christian Bastard · Ardouval, FR
• Francois Delhommeau · Antony, FR
• William Vainchenker · Paris, FR

Key dates

• Filing date: Jun 8, 2016
• Grant date: May 26, 2020
• Expiry date: Mar 11, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.